Mirum Pharmaceuticals Completes $690M Convertible Notes Offering at 30% Premium, Refinances Debt
MIRM has more than doubled off its 52-week low of $42.89.
Summary
Mirum Pharmaceuticals finalized a $690 million convertible senior notes offering, priced at a 30% premium, to refinance existing debt and bolster its financial position for general corporate purposes and acquisitions.
Key Events · Financing and Capital Events · MIRM
-
$690 Million Convertible Notes Offering Completed
Mirum issued $690.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032, including the full exercise of the initial purchasers' option.
-
Premium Conversion Price Set
The notes feature an initial conversion price of $138.94 per share, representing a 30% premium over the last reported stock price of $106.88 on May 12, 2026.
-
Debt Refinancing and Equity Issuance
Approximately $475.0 million of the net proceeds, along with 3,220,529 shares of common stock, were used to exchange $237.2 million of existing 4.00% Convertible Senior Notes due 2029.
-
Enhanced Financial Flexibility
The remaining net proceeds of approximately $196.6 million will be allocated for general corporate purposes, including potential acquisitions, significantly extending the company's financial runway.
Analysis · MIRM · Life Sciences
Mirum Pharmaceuticals has successfully completed a substantial $690 million convertible senior notes offering, which was priced at a significant 30% premium to its recent stock price. This financing is a critical move for the company, especially following a large Q1 net loss, as it provides substantial capital and improves the balance sheet by refinancing existing 4.00% convertible debt with new 0.00% notes, extending maturity to 2032. While the offering involves immediate and potential future dilution, the favorable terms, including the premium conversion price and zero interest, indicate strong investor confidence and significantly enhance the company's financial runway and flexibility for general corporate purposes and potential acquisitions.
At the time of this filing, MIRM was trading at $95.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $42.89 to $114.99. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.